Nucleic acid aptamers recognizing the extra cellular domain of alpha7 / beta1 integrin dimers and uses thereof
Aptamers targeting alpha7/beta1 integrin dimers provide selective and efficient delivery of therapeutic molecules to skeletal muscle fibers and satellite cells, addressing the challenges of current delivery systems and demonstrating therapeutic and diagnostic efficacy.
Patent Information
- Application Number
- PCT/IB2025/053587
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-05
- Filing Date
- 2025-04-04
- Publication Date
- 2025-10-09
AI Technical Summary
Current delivery systems for therapeutic molecules to skeletal muscle, particularly targeting satellite cells, face challenges in selective and efficient uptake due to the vast extension of the tissue and lack of precise targeting, especially when administered systemically.
Development of aptamers that selectively bind to the alpha7/beta1 integrin dimer, a surface protein highly enriched in skeletal muscle fibers and satellite cells, allowing efficient delivery of therapeutic molecules, including nanoformulations, even to inaccessible muscles like the diaphragm, and targeting aberrantly expressing tumor cells.
The aptamers demonstrate high affinity and specificity for alpha7/beta1 integrin dimers, enabling efficient delivery to skeletal muscle fibers and satellite cells, stimulating muscle regeneration and showing therapeutic potential in animal models, while also being useful for diagnostic and research applications.